The Pharmacogenomic Era in Asia: Potential Roles and Challenges for Asian Pharmacists

Lee, Yin Fai; Kwok, Ritchie Ching Chi; Wong, Ian Chi Kei; Lui, Vivian Wai Yan

doi:10.4172/2153-0645.1000164

Cited by 3 publications

(5 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is a global concern to increase pharmacogenetic testing to ensure drug safety and enhance drug efficacy [125,126]. However, most GWAS to identify drug-response related variants have been performed in the western populations and others have lagged behind [7,127,128]. It is important to understand the interpopulation or interethnic variability in drug response so that population/ethnicity-specific guidelines can be produced.…”

Section: Resultsmentioning

confidence: 99%

Heterogeneity in the distribution of 159 drug-response related SNPs in world populations and their genetic relatedness

2020

View full text Add to dashboard Cite

Interethnic variability in drug response arises from genetic differences associated with drug metabolism, action and transport. These genetic variations can affect drug efficacy as well as cause adverse drug reactions (ADRs). We retrieved drug-response related single nucleotide polymorphism (SNP) associated data from databases and analyzed to elucidate population specific distribution of 159 drug-response related SNPs in twenty six populations belonging to five super-populations (African, Admixed Americans, East Asian, European and South Asian). Significant interpopulation differences exist in the minor (variant) allele frequencies (MAFs), linkage disequilibrium (LD) and haplotype distributions among these populations. 65 of the drug-response related alleles, which are considered as minor (variant) in global population, are present as the major alleles (frequency �0.5) in at least one or more populations. Populations that belong to the same super-population have similar distribution pattern for majority of the variant alleles. These drug response related variant allele frequencies and their pairwise LD measure (r 2) can clearly distinguish the populations in a way that correspond to the known evolutionary history of human and current geographic distributions, while D' cannot. The data presented here may aid in identifying drugs that are more appropriate and/or require pharmacogenetic testing in these populations. Our findings emphasize on the importance of distinct, ethnicity-specific clinical guidelines, especially for the African populations, to avoid ADRs and ensure effective drug treatment.

show abstract

Section: Resultsmentioning

confidence: 99%

Heterogeneity in the distribution of 159 drug-response related SNPs in world populations and their genetic relatedness

2020

View full text Add to dashboard Cite

show abstract

“…A recent study conducted in Singapore observed that 30% of adverse drug reactions (ADRs) were caused by at least one drug with a PGx clinical annotation, suggesting the potential to prevent ADR occurrence via PGx testing ( Chan et al, 2016 ). Despite PGx testing demonstrating its potential to enhance medication safety and efficacy ( Dunnenberger et al, 2015 ), its utility in clinical practice has been suboptimal ( Chan et al, 2017 ), specifically in Asia ( Lee et al, 2017 ). The lack of PGx education is an often-cited barrier to the widespread implementation of PGx ( Mccullough et al, 2011 ; Kisor et al, 2015 ; Luzum and Luzum, 2016 ; Kisor and Farrell 2019 ).…”

Section: Introductionmentioning

confidence: 99%

“…A study conducted on physicians observed that a 45 min PGx presentation can improve their attitudes toward PGx testing ( Luzum and Luzum 2016 ). PGx educational courses would have to be constantly updated to ensure sustainable PGx assimilation into routine clinical practice ( Dunnenberger et al, 2015 ; Lee et al, 2017 ). There have been scarce resources available for doctors to learn pharmacogenomics online.…”

Section: Introductionmentioning

confidence: 99%

Pharmacogenomics Implementation Training Improves Self-Efficacy and Competency to Drive Adoption in Clinical Practice

Adesta¹,

Mahendra²,

Junusmin³

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

Background: Administration of pharmacogenomics (PGx) testing in clinical practice has been suboptimal, presumably due to lack of PGx education. Here, we aim to evaluate the standpoint of PGx testing among a diverse group of healthcare professionals (HCPs) through conducting surveys before and after training.Materials and Methods: Training modules were designed to cover three key learning objectives and deployed in five sections. A pre- and post-training survey questionnaire was used to evaluate participants’ self-assessments on employing PGx in clinical practice.Results and Conclusion: Out of all enrollments, 102 survey responses were collected. Overall, respondents agree on the benefits of PGx testing, but have inadequate self-efficacy and competency in utilizing PGx data. Our results show that a 90 min long training significantly improves these, and could lead to greater anticipation of PGx adoption.

show abstract

“…A recent study conducted in Singapore observed that 30% of adverse drug reactions (ADRs) were caused by at least one drug with a PGx clinical annotation, suggesting the potential to prevent ADR occurrence via PGx testing [3]. Despite PGx testing demonstrating its potential to enhance medication safety and efficacy [4], its utility in clinical practice has been suboptimal [5], specifically in Asia [6]. The lack of PGx education is an often-cited barrier to the widespread implementation of PGx [7–10].…”

Section: Introductionmentioning

confidence: 99%

“…A study conducted on physicians observed that a 45-minute PGx presentation can improve their attitudes towards PGx testing [7]. PGx educational courses would have to be constantly updated to ensure sustainable PGx assimilation into routine clinical practice [4,6]. This study is novel because this is the first training material that considers the current level of understanding in Asian healthcare professionals towards pharmacogenomics.…”

Section: Introductionmentioning

confidence: 99%

Pharmacogenomics implementation training improve self-efficacy and competency to drive adoption in clinical practice

Adesta¹,

Mahendra²,

Junusmin³

et al. 2020

Preprint

View full text Add to dashboard Cite

BackgroundAdministration of pharmacogenomics (PGx) testing in clinical practice has been suboptimal, presumably due to lack of PGx education. Here, we aim to evaluate the standpoint of PGx testing among a diverse group of healthcare professionals (HCPs) through conducting surveys before and after training.Materials & MethodsTraining modules were designed to cover 3 key learning objectives and deployed in 5 sections. A pre- and post-training survey questionnaire was used to evaluate participants self-assessments on employing PGx in clinical practice.Results & ConclusionOut of all enrollments, 102 survey responses were collected. Overall, respondents agree on the benefits of PGx testing, but have inadequate self-efficacy and competency in utilizing PGx data. Our results show that training significantly improve these, and even leading to greater anticipation of PGx adoption.

show abstract

The Pharmacogenomic Era in Asia: Potential Roles and Challenges for Asian Pharmacists

Cited by 3 publications

References 14 publications

Heterogeneity in the distribution of 159 drug-response related SNPs in world populations and their genetic relatedness

Heterogeneity in the distribution of 159 drug-response related SNPs in world populations and their genetic relatedness

Pharmacogenomics Implementation Training Improves Self-Efficacy and Competency to Drive Adoption in Clinical Practice

Pharmacogenomics implementation training improve self-efficacy and competency to drive adoption in clinical practice

Contact Info

Product

Resources

About